Combining menin inhibitors with different inhibitors, such as CDK6, CDK9, XPO1, BET, MOZ, LSD1, and CBP/p300, also induces synergistic lethality in AML cells harboring different mutations [80,81]. This evidence concerns the gene MEN1 and acute myeloid leukemia.